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Background: Decreased expression of glucose transporter protein GLUT4, encoded by the solute carrier 2A4 (Slc2a4)
gene, is involved in obesity-induced insulin resistance. Local tissue inflammation, by nuclear factor-κB (NFκB)-mediated
pathway, has been related to Slc2a4 repression; a mechanism that could be modulated by statins. Using a model of
obesity with insulin resistance, this study investigated whether (1) inflammatory markers and Slc2a4 expression are
altered; (2) atorvastatin has beneficial effects on inflammation and Slc2a4 expression; and (3) inhibitor of NFκB (IKK)/NFκB
pathway is involved in subcutaneous adipose tissue (SAT).
Findings: Obese mice showed insulin resistance, decreased expression of Slc2a4 mRNA (66%, P < 0.01) and GLUT4 protein
(30%, P < 0.05), and increased expression of interleukin 6 (Il6) mRNA (44%, P < 0.05) in SAT. Obese mice treated with
atorvastatin had enhanced in vivo insulin sensitivity, besides increased Slc2a4/GLUT4 expression and reduced Il6
expression in SAT. No alterations of tumor necrosis factor-α, interleukin 1β and adiponectin expression or IKKα/β
activity in SAT of obese mice or obese mice treated with atorvastatin were observed.
Conclusions: Atorvastatin has beneficial effect upon glycemic homeostasis, which may be related to its positive
impact on Il6 and Slc2a4/GLUT4 expression in SAT.
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The glucose transporter protein GLUT4 is responsible for
insulin-mediated glucose uptake in adipose tissue and
skeletal muscle, and plays an important role in glycemic
homeostasis [1]. In adipocytes, several transcriptional fac-
tors regulate Slc2a4 gene, which encodes for GLUT4 pro-
tein, including the nuclear factor-κB (NFκB) [2-4].
Obesity is associated with insulin resistance and re-
duced Slc2a4/GLUT4 expression in both muscle and fat
[2,5]. On the other hand, studies on transgenic mice
have pointed out that overexpression of GLUT4 in fat
enhances in vivo glucose tolerance and insulin sensitivity
[6]. Furthermore, since the identification of proinflam-
matory cytokine TNF-α in fat [7] and its relationship to* Correspondence: danifuruya@yahoo.com
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unless otherwise stated.insulin resistance [8], obesity has been closely related to
a low grade chronic inflammatory state.
Several studies have demonstrated that statins exert
pleiotropic actions besides cholesterol lowering. Re-
cently, some studies have reported evidences for anti-
inflammatory and insulin sensitizing effects of statin in
visceral adipose tissue (VAT) of glutamate monosodium-
induced obese mice [2,9]. In addition, there are evidences
that IKK/NFκB pathway is involved in the Slc2a4 gene
expression in VAT [2].
Not only VAT but also subcutaneous adipose tissue
(SAT) have been associated to insulin resistance [10].
Considering that SAT is responsible for most of systemic
free fatty acids, which are known to induce peripheral
insulin resistance, SAT could have more impact on insulin
resistance than VAT [11]. Additionally, it is important to
understand molecular differences between VAT and SAT,
because these fat depots have different biological properties,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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present study addresses the effects of atorvastatin on glu-
cose disposal and inflammation focusing on SAT. For that
purpose, we used a previous tested model of obesity and in-




Monosodium glutamate (MSG) was obtained from Sigma
(St. Louis, MO) and atorvastatin, from Pfizer (Guarulhos,
SP, Brazil). Trizol, DNaseI and Platinum SYBR Green
qPCR SuperMix UDG were obtained from Invitrogen
(Carlsbad, CA). GoTaq DNA Polymerase was obtained
from Promega (Madison, WI). Antibodies for phosphory-
lated IKK-α/β (Ser180/Ser181) were obtained from Cell
Signaling (Beverly, MA) and for GLUT4 from Chemicon
(Temecula, CA). Plasma glucose, AST and ALT were
assayed with kits purchased from CELM (São Paulo, SP).
Glycemia for intravenous insulin tolerance test (IVITT) was
measured with a glucometer (Precision QID, Medisense,
Bedford, MA).
Animals treatments
Obesity induction in male offspring mice (CD1) was car-
ried out by subcutaneous injections of MSG (2 mg/g
body weight) from days one to five, and on day seven
after birth [2]. Control mice were injected with saline so-
lution. Animals were weaned and allowed free access to
standard rodent chow and water ad libitum until
19 weeks of age, when atorvastatin treatment of obese
mice started. Atorvastatin was given in chow (0.1% w/w)
for four weeks. At the end of treatment (23-week-old
mice) the obesity degree was estimated by Lee obesityTable 1 Characteristics and metabolic profile of the mice und
CTL
Body weight (g) 32.9 ± 0.6
Lee Obesity Index (x 100) 33.1 ± 0.5
Absolute SAT weight (g) 0.43 ± 0.08
Relative SAT weight (x 100) (g) 1.92 ± 0.62
Absolute VAT weight (g) 0.21 ± 0.01
Relative VAT weight (x100) (g) 0.64 ± 0.04
Plasma cholesterol (mmol/L) 1.87 ± 0.09
Plasma glucose (mmol/L) 8.83 ± 0.27
Plasma insulin (pmol/L) 532.6 ± 28.5
kITT (%/min) 4.84 ± 0.32
Plasma AST activity (U/L) 19.6 ± 2.1
Plasma ALT activity (U/L) 12.6 ± 0.7
SAT, subcutanous adipose tissue, VAT, visceral adipose tissue, kITT, glucose disappeara
cholesterol, glucose and insulin concentration and kITT were obtained from mice subje
parameters), and 3 to 7 (metabolic hormonal parameters) animals. *P < 0.05, **P <
of variance and Student–Newman–Keuls post hoc test.index [body weight (g)1/3/nasoanal length (cm)], and
subcutaneous adipose tissue (SAT) from abdominal, lat-
eral and dorsal regions, as well as blood samples were
collected under anesthesia (50 mg/kg b.w. sodium
pentobarbital, i.p.). Blood samples for glucose, insulin,
cholesterol, AST and ALT quantification were collected
from retro-ocular bleeding. For ITT experiments, an-
other group of animals was used and blood samples were
collected from the tail vein. Mice were euthanized with an
overdose of sodium pentobarbital. All procedures were
approved by the Ethical Committee for Animal Research
of the Institute of Biomedical Sciences, University of São
Paulo (123/2005).
Plasma analysis
Levels of plasma glucose, insulin, cholesterol, activity of
aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) were measured as previously described
[14,15] after 4-hour restricted feeding.
Insulin sensitivity was analyzed by measuring the glucose
disappearance constant (kITT) during the intravenous in-
sulin tolerance test (IVITT) [14].
GLUT4 protein and Slc2a4 mRNA analysis
GLUT4 was analyzed in SAT by Western blotting and
Slc2a4 mRNA by real-time PCR as previously described
[4]. For Western blotting, protein-loaded control was
checked by analyzing post-transferring Coomassie-stained
gels [16]. For real-time PCR, several housekeeping genes,
such as mouse Rplp0 (36B4), Gapdh and Actb were tested.
Rplp0 was used for normalization. The primer sequences
of the following genes, mouse Slc2a4 [GenBank:
NM_009204], Il6 [NM_031168], Tnf [NM_013693], Il1b
[NM_008361], Rplp0 [NM_007475], Gapdh [NM_008084]er investigation
OB OBA
32.5 ± 0.8 32.8 ± 0.5
36.8 ± 0.8 ** 36.0 ± 0.4**
1.69 ± 0.14 *** 1.47 ± 0.17***
5.22 ± 0.48** 4.47 ± 0.52**
1.31 ± 0.03 *** 1.35 ± 0.13 ***
4.04 ± 0.16 *** 4.09 ± 0.3 ***
1.88 ± 0.13 1.33 ± 0.05** ##
8.4 ± 0.52 7.8 ± 0.05
761.8 ± 19.2*** 640.3 ± 10.1* ##
2.96 ± 0.30* 4.67 ± 0.62#
20.6 ± 2.0 21.5 ± 0.5
14.6 ± 1.6 15.9 ± 0.4
nce constant obtained in the intravenous insulin tolerance test. Data from plasma
cted to 4-hour food deprivation. Data are means S.E. of 4 to 6 (morphological
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Figure 1 Slc2a4 mRNA (A) and GLUT4 protein (B) expression in
subcutaneous white adipose tissue. Mice were separated into
several groups: lean untreated (CTL, white bars), obese untreated
(OB, black bars) or obese atorvastatin-treated (OBA, gray bars) mice.
In (A) and (B), relative values of mRNA or protein content (bottom)
are shown. In B (top), image of a typical experiment. Slc2a4 mRNA
expression was analyzed by Real-time PCR, normalized by Rplp0 (A),
and GLUT4 protein expression by Western blotting (B), normalized
by total protein analysis with Coomassie Blue-stained gel (C). Data are
expressed as means ± S.E. of 5–6 (Slc2a4 mRNA) and 5–6 (GLUT4 protein)
animals per group. *P < 0.05 and **P < 0.01 vs. CTL; # P < 0.05 and ##
P < 0.01 vs. OB; ANOVA and Student–Newman–Keuls post hoc test.
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are as follows: Adipoq [NM_009605] (fw, 5′-TGGATCTG
ACGACACCAAAA-3′; rv, 5′-ATCCAACCTGCACAAG
TTCC-3′) and Actb [NM_007393] (fw, 5′-ACTGGGACG
ACATGGAGAAG-3′; rv, 5′-GGGGTGTTGAAGGTCTC
AAA-3′).
Phosphorylated and total IKK content
SAT was homogenized in ice-cold extraction buffer
[100 mM Tris (pH 7.4), 10 mM EDTA, 10 mM sodium
pyrophosphate, 100 mM sodium fluoride, 10 mM so-
dium vanadate, 2 mM PMSF, 1% Triton X-100, 0.01 mg/
mL aprotinin] and centrifuged at 15000 g, 4°C, for
20 min. The supernatants were used to evaluate phos-
phorylated IKK-α/β and total IKK-β content, which were
assayed by Western blotting using anti-phospho-IKK-α
(Ser180)/β(Ser181) and anti-IKK-β antibody; respectively
(1:1000), followed by standard chemiluminescence de-
tection, and normalization using total protein analysis of
post-transferring Coomassie-stained gels [16].
Statistical analysis
All data are expressed as means ± S.E. Comparison of
the means were performed by one-way analysis of vari-
ance (ANOVA), with Student–Newman–Keuls as a post
hoc test.
Results
Although untreated obese mice (OB) and atorvastatin-
treated obese mice (OBA) showed similar body weight
to that observed in control mice (CTL), the significant
higher Lee obesity index indicated that both groups
were obese (Table 1). Besides, both OB and OBA
showed augmentation of absolute (293% and 241% vs
CTL, P < 0.001, respectively) and relative (171% and
132% vs CTL, P < 0.01, respectively) SAT weight when
compared to CTL (Table 1).
OB presented hyperinsulinemia and decreased glucose
disappearance constant (38% vs CTL, P <0.05) in IVITT,
depicting the whole body insulin-resistant condition
(Table 1). Moreover, as evident in Figure 1, the expression



































































Figure 2 Tnf (A), Il6 (B), Adipoq (C) and Il1b (D) mRNA content in subcutaneous adipose tissue. Mice were separated into several groups: lean
untreated (CTL, white bars), obese untreated (OB, black bars) or obese atorvastatin-treated (OBA, gray bars) mice. The mRNA was analyzed by real-time PCR,
and Rplp0 gene was used for normalization. The values are means ± S.E. of 6 animals per group. *P < 0.05 vs. CTL; #P < 0.05 vs. OB; ANOVA and
Student-Newman-Keuls post hoc test.
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respectively), indicating the participation of this territory
in the whole body glycemic homeostasis.
Interestingly, atorvastatin treatment did not only reduce
plasma cholesterol (Table 1), but also had a positive im-
pact on glucose metabolism, reducing the level of insuli-
nemia and increasing the insulin sensitivity of OBA as
measured by IVTT (Table 1). Atorvastatin also restored
the expression of Slc2a4 mRNA and GLUT4 protein in
SAT of obese mice (Figure 1). Additionally, the drug did
not alter the plasma activity of AST and ALT, indicating
no apparent hepatotoxicity (Table 1).
In order to verify the effect of obesity and atorvastatin
treatment upon inflammation in SAT, the expression of
some cytokines were investigated. OB showed increased
Il6 mRNA expression in SAT (44% vs CTL, P < 0.05),
but unchanged Tnf, Il1b or Adipoq gene expression (Fig-
ure 2). Moreover, atorvastatin treatment was able to drastic-
ally reduce Il6 mRNA expression (44% vs OB, P< 0.05) in
SAT (Figure 2).
The IKK/NFκB pathway was accessed in SAT. Total
IKK-β content and phosphorylated IKK-α/β in SAT ofOB and OBA were unaltered when compared to CTL
(Figure 3).Discussion
The current study demonstrated that atorvastatin treat-
ment restores GLUT4 protein and mRNA expression in
SAT of OB, contributing to the amelioration of whole-
body insulin resistance.
It has been reported that atorvastatin has beneficial im-
pacts on inflammation and glucose metabolism. Our la-
boratory recently demonstrated that OBA had reduced
circulating cytokines and reduced cytokines expression in
VAT, which resulted in insulin sensitizing effects [2]. SAT
and VAT show distinct physiological characteristics such
as cytokine expression [17] and insulin signaling [18].
Therefore, by using an established model of obesity and
insulin resistance, and an anti-inflammatory treatment
(atorvastatin), this study analyzed the SAT of obese mice.
Many reports have shown that reduced GLUT4 expres-
sion is related to insulin resistance, and improvement of































Figure 3 Total IKK-β and phosphorylated IKKα/β in subcutaneous
adipose tissue. Mice were separated into several groups: lean
untreated (CTL, white bars), obese untreated (OB, black bars) or
obese atorvastatin-treated (OBA, gray bars) mice. In (A) and (B), on
top, images of one typical experiment; and, on bottom, relative
values of total IKK-β and phosphorylated IKKα/β protein content are
shown. Normalization was performed by total protein analysis with
Coomassie Blue-stained gel (C). Data are means ± S.E. of 4–7 animals
per group.
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of GLUT4 have a striking reduction in glucose uptake by
adipocytes [20]. In contrast, overexpression of GLUT4 in
adipose tissue increases glucose influx into adipocytes [6].
The present data clearly show that obese mice developed
insulin resistance which was accompanied by reducedSlc2a4 mRNA and protein content in SAT. It has been re-
ported that Slc2a4 mRNA [21] and protein [22] expres-
sion is reduced in SAT of obese women. Regarding SAT
of obese mice, this is the first report investigating Slc2a4
expression. It has been reported that OB mice present re-
duced Slc2a4 mRNA and GLUT4 protein expression in
VAT [2,5]. Therefore, it can be assumed that the reduction
of Slc2a4/GLUT4 expression in both SAT and VAT con-
tributes to the whole-body insulin resistance in this animal
model of obesity. On the other hand, atorvastatin was able
to restore Slc2a4 mRNA and protein content not only in
VAT [2], but also in SAT of OB, contributing for amelior-
ation of insulin resistance.
Obesity is considered as a low grade chronic inflamma-
tory state [2,23]. OB showed increased Il6 expression in
SAT, but showed no alteration in Tnf, Il1b and Adipoq ex-
pression. The literature concerning the impact of obesity
on Tnf expression in mice SAT is contentious [24,25]. As
to Il1b expression in SAT, a single study shows reduction
in obese mice [25]. Furthermore, few reports have shown
Il6 increase in VAT of obese mice [2,17], but to date there
has been no report about obesity impact on Il6 expression
in SAT of mice. Taking into account that IL-6 can re-
duce Slc2a4/GLUT4 expression in adipocytes [26], the
present findings point out that IL-6 may be an import-
ant repressor of the Slc2a4 gene in SAT but the involved
mechanisms still needs clarification.
Finally, we are, for the first time, reporting that IKK
content and phosphorylation are not altered in SAT of
OB. IKK/NFκB negatively modulates the expression of
Slc2a4 gene [2-4,27], and we have demonstrated that the
reduced expression of Slc2a4/GLUT4 in VAT of OB cor-
relates to enhanced IKK phosphorylation [2]. However,
in SAT, the present findings could not confirm the in-
volvement of this inflammatory pathway in the modula-
tion of Slc2a4 gene.
In conclusion, Slc2a4 expression in SAT is reduced in
OB, which contributes to the impairment of glycemic
homeostasis. Atorvastatin treatment improves insulin re-
sistance which may be related to its positive impact on
Il6 and Slc2a4/GLUT4 expression in SAT.
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